Viatris Inc. (United States) is linked to 8 FDA-registered manufacturing sites. 27 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Viatris Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/viatris-inc

Overview

Viatris Inc. was formed through the merger of Mylan N.V. and Upjohn, a division of Pfizer. It is a global pharmaceutical company that provides a broad range of medications, including generics and specialty drugs. The company focuses on increasing patient access to affordable medications.

Core services & business areas

Regulatory AffairsCommercializationSupply Chain ManagementManufacturingPharmaceutical ManufacturingDistribution

Therapeutic areas

Registered manufacturing sites (8)

Physical sites registered with the US FDA and resolved to Viatris Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

27 FDA enforcement records linked to this company.

  • recall — Class III2026-10-28

    Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications

  • recall — Class II2026-04-15

    Failed Dissolution Specifications

  • recall — Class II2025-01-22

    Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

  • recall — Class II2025-01-22

    Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-12-18

    Superpotent Drug and Subpotent Drug: potency failures obtained

  • recall — Class II2024-07-24

    Failed Impurities/Degradation Specifications

  • recall — Class II2024-07-24

    Failed Impurities/Degradation Specifications

  • recall — Class III2024-05-08

    Failed Tablet/Capsule Specifications: There is a potential for the imprint, M 122, to be missing on some tablets.

  • recall — Class II2023-06-14

    CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

  • recall — Class II2022-11-23

    Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.

  • recall — Class I2022-11-16

    Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.

  • recall — Class II2022-10-05

    Presence of Particulate Matter: A complaint was received for the presence of a single strand of hair in one vial.

  • recall — Class II2022-05-18

    Failed Dissolution Specifications: low out of specification results for dissolution.

  • recall — Class II2022-05-11

    Failed Dissolution Specifications: low out-of-specification dissolution test results observed.

  • 4832012-07-26

    Complaint Handling Procedure

  • 4832010-02-17

    Identification of persons involved, each significant step

  • 4832010-02-17

    Procedures not in writing, fully followed

For suppliers

Is this Viatris Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.